Evidence map›Paper›PMID 31718254›Full record

Trial reportJournal of child and adolescent psychopharmacology2020

Phase II/III Study of Lisdexamfetamine Dimesylate in Japanese Pediatric Patients with Attention-Deficit/Hyperactivity Disorder.

Hironobu Ichikawa, Tasuku Miyajima, Yushiro Yamashita, Masakazu Fujiwara, Akimasa Fukushi, Kazuhiko Saito

Open access · hybridAbstract readClinical Trial, Phase IIClinical Trial, Phase IIIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of child and adolescent psychopharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Observational
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Hironobu IchikawaJapan Developmental Disorders Network, Tokyo, Japan.
Tasuku MiyajimaDepartment of Education for Childcare, Tokyo Kasei University, Saitama, Japan.
Yushiro YamashitaDepartment of Pediatrics and Child Health, Kurume University School of Medicine, Fukuoka, Japan.
Masakazu FujiwaraBiostatistics Center, Shionogi & Co., Ltd, Osaka, Japan.
Akimasa FukushiClinical Research Department, Shionogi & Co., Ltd, Osaka, Japan.
Kazuhiko SaitoAiiku Counseling Office, Aiiku Research Institute, Imperial Gift Foundation Boshi-Aiiku-Kai, Tokyo, Japan.
Shionogi (Japan) · JPDaiichi Kogyo Seiyaku (Japan) · JPKurume University · JPTokyo Kasei University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AdolescentAttention Deficit Disorder with HyperactivityCentral Nervous System StimulantsChildDose-Response Relationship, DrugDouble-Blind MethodFemaleHumansJapanLisdexamfetamine DimesylateMaleCentral Nervous System StimulantsLisdexamfetamine Dimesylateadolescentsattention-deficit/hyperactivity disorderchildrenefficacyJapanese patientslisdexamfetamine dimesylatesafety

Identifiers

PMID31718254
PMCPMC7041327
OpenAlexW2987638586

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.